TY - JOUR
T1 - Ketamine for pain
T2 - An update of uses in palliative care
AU - Prommer, Eric E.
PY - 2012/4/1
Y1 - 2012/4/1
N2 - Ketamine is a lipophilic, general anesthetic. When given at subanesthetic doses, it also has been found to be an effective analgesic, with efficacy in cancer-associated neuropathic pain, ischemic pain, and regional pain syndromes. It can be administered orally, intravenously, subcutaneously, and topically, and interacts with several receptors important in pain management, most importantly the N-methyl-D aspartate (NMDA) receptor. Blockade of the NMDA receptor is associated with reversal of opioid tolerance. Ketamine is metabolized via cytochrome P450 3A4, although no significant interactions have been reported. Ketamine is considered one of the World Health Organization (WHO) essential drugs for the management of refractory pain.
AB - Ketamine is a lipophilic, general anesthetic. When given at subanesthetic doses, it also has been found to be an effective analgesic, with efficacy in cancer-associated neuropathic pain, ischemic pain, and regional pain syndromes. It can be administered orally, intravenously, subcutaneously, and topically, and interacts with several receptors important in pain management, most importantly the N-methyl-D aspartate (NMDA) receptor. Blockade of the NMDA receptor is associated with reversal of opioid tolerance. Ketamine is metabolized via cytochrome P450 3A4, although no significant interactions have been reported. Ketamine is considered one of the World Health Organization (WHO) essential drugs for the management of refractory pain.
UR - http://www.scopus.com/inward/record.url?scp=84859796838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859796838&partnerID=8YFLogxK
U2 - 10.1089/jpm.2011.0244
DO - 10.1089/jpm.2011.0244
M3 - Review article
C2 - 22500483
AN - SCOPUS:84859796838
SN - 1096-6218
VL - 15
SP - 474
EP - 483
JO - Journal of Palliative Medicine
JF - Journal of Palliative Medicine
IS - 4
ER -